Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Kovack Advisors Inc.

Kovack Advisors Inc. increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 88.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,599 shares of the specialty pharmaceutical company’s stock after acquiring an additional 26,628 shares during the period. Jazz Pharmaceuticals makes up about 0.8% of Kovack Advisors Inc.’s investment portfolio, making the stock its 16th largest position. Kovack Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $6,816,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after purchasing an additional 29,960 shares during the period. Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock worth $168,222,000 after buying an additional 57,717 shares during the period. Polaris Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 2.2% during the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after buying an additional 27,100 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after buying an additional 224,865 shares during the period. Finally, Baupost Group LLC MA increased its position in shares of Jazz Pharmaceuticals by 23.7% in the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after acquiring an additional 160,000 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.5 %

NASDAQ JAZZ traded down $1.56 during trading on Thursday, reaching $103.53. The company’s stock had a trading volume of 304,674 shares, compared to its average volume of 786,882. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $6.53 billion, a PE ratio of 21.35, a PEG ratio of 1.61 and a beta of 0.58. Jazz Pharmaceuticals plc has a 1-year low of $102.86 and a 1-year high of $146.70. The business has a 50-day moving average price of $108.70 and a 200-day moving average price of $116.35.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, research analysts forecast that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

JAZZ has been the subject of a number of recent analyst reports. Piper Sandler raised their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Truist Financial reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Stifel Nicolaus lifted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $188.62.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.